Panacea Venture is a healthcare venture fund with global vision and reach dedicated to transforming lives through promising innovation.

Panacea Venture

Panacea Venture is a life sciences venture capital firm with global vision and presence across three continents. The firm was founded in 2017 and is currently managing four funds investing in early-stage companies through public investments. Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale. The investment team has more than 100 years of combined investing experience and, along with venture partners and advisors, provides broad coverage across emerging and established biotech, diagnostic and medtech sectors. In addition, Panacea’s highly experienced team has a strong track record navigating portfolio companies to success.  

New Amsterdam Pharma

Johnson & Johnson Innovation – JLABS recognizes that unlocking investment opportunities is every start-up's biggest challenge and continue facilitating connections between regional and global investment funds and Singapore’s life-science ecosystem.
 
On August 29, JLABS will introduce Panacea Venture at the stunning co11ab Novena in Singapore! Our Founder and Managing Partner, James Huang brings an impressive background as an investor, entrepreneur, and corporate experience at companies previously acquired by big pharma. There will also be a star panel discussion featuring distinguished industry experts alongside James, including Yue (Shelby) Zhang and David M Epstein being moderated by JLABS Ronne Yeo

#biotech #investing #JLABS #lifesciences

We are pleased to announce that the Investigational New Drug (“IND”) application of Cyclosporine A (“CsA”) Ophthalmic Gel for the treatment of moderate to severe dry eye disease (“DED”) has been approved by the National Medical Products Administration (the “NMPA”) of China.  This Phase III clinical trial has been designed to closely follow the requirements outlined by the Center for Drug Evaluation (the “CDE”) in its Technical Guidelines on Clinical Trials for Therapeutic Drugs for Dry Eyes issued in September 2023.
 
We are also pleased to announce that on 5 August 2024, the last patient last visit was completed for the two-year Phase III clinical trial (“China CHAMP”) of our core product NVK002, a treatment for myopia progression control. 

For more information, please visit:
https://lnkd.in/d5M8H4hA

#zhaoke #ophthalmology #healthcare #eyecare #pharmaceutical #biotech #dryeye #myopia

Congratulations to Human Longevity for completing Series B financing further supporting their efforts of developing innovative solutions to help people live longer, healthier lives!

Thank you Human Longevity, Inc. for inviting me to give a keynote on the latest advancements in #longevitymedicine. Tailoring the interventions to an individual is crucial for maximizing their effectiveness. Honored to talk more about it on July 10th.
#longevityphyscian #healthylongevity

link: https://lnkd.in/d6gqpSgG

The FDA’s official press release regarding the START Pilot Program includes Myrtelle as 1 of 4 CBER participants. Read the full article below! #fda #STARTProgram #myrtelle
https://bit.ly/3zoOecV

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Aug 31, 2024 1:29 AM	96f6820c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
peers	general	Aug 31, 2024 1:29 AM	ba766d5d
news basic	general	Aug 31, 2024 1:29 AM	b213e51f
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

PANA

COM:PANACEAVENTURE

Panacea Venture